Ticker Symbol: ETNB
89bio Inc
$16.50 - 02-12-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001785173
Company Profile
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: www.89bio.com
CEO: N/A
Tags:
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $14.40
Change:
-$0.02
(
-0.14%)
Days Range: $13.89 - $14.49
Beta: 0.23
52wk. High: $22.93
52wk. Low: $6.63
Ytd. Change 13.14%
50 Day Moving Average: $14.18
200 Day Moving Average: $16.55
Shares Outstanding: 75480884
Valuation
Market Cap: 108.7B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A